Second COVID booster cuts long COVID risk by 82% in Brazilian study

Key Findings

🧠 Brain Fog Linked to Specific Blood Markers

Japanese researchers studied 33 adults with long COVID brain fog and found measurable changes in both brain blood flow and plasma proteins:

• Cognitive test scores correlated with decreased blood flow in the left occipital lobe and increased flow in the right occipital lobe

• Memory and processing speed scores were linked to plasma levels of neurofilament light chain (a marker of nerve damage)

• Processing speed also correlated with glial fibrillary acidic protein levels (indicating brain cell inflammation)

🔬 Kids' Long COVID Shows Immune System Gone Haywire

Researchers analyzed blood samples from 99 children with long COVID compared to 18 without, revealing widespread immune dysfunction:

• Children with long COVID had overactivated T-cells, B-cells, and natural killer cells alongside disrupted innate immunity

• Their antibody response was impaired—lower levels of protective IgG and IgA antibodies against the virus

• A protein called CCR6 on immune cells distinguished long COVID cases with 79% accuracy

💊 Paxlovid May Prevent Some Long COVID Symptoms

A meta-analysis of 19 studies found that taking nirmatrelvir/ritonavir (Paxlovid) during acute COVID reduced long COVID risk by 15%:

• The antiviral showed protective effects for cardiovascular, lung, blood clot, neurological, and metabolic complications

• No significant benefits were seen for cough, asthma, anxiety, sleep problems, or loss of taste/smell

• The analysis included data from multiple countries and healthcare systems

🩸 Patient Antibodies Disrupt Cell Energy Production

Scientists isolated antibodies from 39 ME/CFS patients (including 15 with post-COVID ME/CFS) and applied them to healthy cells:

• The antibodies caused mitochondria—cellular power plants—to fragment in human endothelial cells

• This fragmentation occurred without reducing the cells' ability to produce ATP (cellular energy)

• Different antibody patterns emerged between general ME/CFS and post-COVID ME/CFS patients

🏥 Major Trial Launches for Long COVID Heart Problems

The NIH's RECOVER initiative designed a platform trial to test three treatments for postural orthostatic tachycardia syndrome (POTS) in long COVID:

• The study will test intravenous immunoglobulin (IVIG), the heart rate drug ivabradine, and coordinated non-drug care

• Participants get randomized to drug treatments plus either specialized care coordination or usual care

• The trial uses adaptive design, allowing researchers to modify the study based on emerging results

🧬 Ethnic Differences Reveal Long COVID Diagnosis Gaps

Analysis of 17.8 million adults in England found significant variation in long COVID diagnoses across ethnic groups:

• Bangladeshi adults had 21% higher diagnosis rates than White British, while Indian adults had 23% lower rates

• Black Caribbean adults showed 15% higher rates, but Black African adults had 39% lower rates

• These differences persisted even after accounting for socioeconomic factors and COVID testing history